Corvus Pharmaceuticals, Inc.CRVSNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +36.20% | +39.37% | +47.08% | +30.25% | +24.19% |
| Weighted Average Shares Diluted Growth | +36.20% | +39.37% | +53.25% | +30.25% | +24.19% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1909.09% | +242.86% | +291.38% | +112.30% | -85.52% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +13.23% | +51.27% | +48.28% | +38.57% | +36.83% |
| Book Value per Share Growth | -79.43% | -39.59% | +0.52% | +20.24% | +365.70% |
| Debt Growth | -79.05% | -18.34% | +10.87% | +54.71% | +185.59% |
| R&D Expense Growth | +31.70% | +49.39% | +82.90% | +91.37% | +61.89% |
| SG&A Expenses Growth | +27.46% | +29.00% | +13.36% | +31.08% | +4.18% |